BOOSTII


New oxygen targets for better survival outcomes in extremely preterm infants

6 June 2013

The three international BOOSTII studies published in the New England Journal of Medicine have found that more of the extremely preterm infants in the group allocated an oxygen saturation target of 91-95% survived to hospital discharge than those in the group with allocated a saturation target of 85-89%. Read the article here.

'Globally, this new evidence will lead to thousands more preterm babies surviving each year', commented Professor William Tarnow-Mordi, head of the WINNER Centre for Newborn Research at CTC.

Professor Tarnow-Mordi and the neonatal team at CTC led the Australian arm of the international BOOSTII studies, whose aim is to determine the safer and more clinically appropriate range for oxygen saturation in extremely preterm infants (those born before 28 weeks' gestation) by measuring survival without disability at 2 years. 'Follow-up is continuing and will be complete this year', added Professor Tarnow-Mordi.

This work was funded by the Australian National Health and Medical Research Council and others; BOOST II Current Controlled Trials number, ISRCTN00842661, and Australian New Zealand Clinical Trials Registry numbers, ACTRN12605000055606 and ACTRN12605000253606.